Metal coordination-based inhibitors of adenylyl cyclase: Novel potent P-site antagonists

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2177-2186

  Levy, Daniel E ^a,b   Bao, Ming ^a   Cherbavaz James, Diana B ^a   Tomlinson, E ^a   Sedlock, David M ^a   Homcy, Charles J ^a   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (9 ADENENYL) 3 (N HYDROXYCARBAMOYL) 4 CYCLOPENTENE; 1 (9 ADENENYL) 3 (N HYDROXYCARBAMOYL)CYCLOPENTANE; 1 (9 ADENENYL) 3 (N HYDROXYCARBAMOYLMETHYL) 4 CYCLOPENTENE; 1 (9 ADENENYL) 3 (N HYDROXYCARBAMOYLMETHYL)CYCLOPENTANE; ADENINE; ADENYLATE CYCLASE; ENZYME INHIBITOR; HYDROXAMIC ACID DERIVATIVE; METAL; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONFORMATION; DRUG DESIGN; DRUG POTENCY; ENTROPY; HUMAN; HUMAN CELL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS;

ADENYLATE CYCLASE; CELL LINE; CHELATING AGENTS; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; ISOENZYMES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037573314     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205604     Document Type: Article

References (22)

1. Toya, Y.; Schwencke, C.; Ishikawa, Y. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase. J. Mol. Cell. Cardiol. 1998, 30, 97-108.
2. Hellevuo, K.; Hoffman, P. L.; Tabakoff, B. Adenylyl cyclases: mRNA and characteristics of enzyme activity in three areas of brain. J. Neurochem. 1996, 67, 177-185.
3. Goldstein, J.; Silberstein, C.; Ibarra, C. Adenylyl cyclase types I and VI but not II and V are selectively inhibited by nitric oxide. Braz. J. Med. Biol. Res. 2002, 35, 145-151.
4. Reprinted from Bioorg. Med. Chem. Lett., Vol. 12, Levy, D. E.; Marlowe, C.; Kane-Maguire, K.; Bao, M.; Cherbavaz, D. B.; Tomlinson, J. E.; Sedlock, D. M.; Scarborough, R. M. Hydroxamate based inhibitors of adenylyl cyclase. Part 1: The effect of acyclic linkers on P-site binding, pp 3085-3088, Copyright 2002, with permission from Elsevier Science.
5. Hamm, H. E. The many faces of G protein signaling. J. Biol. Chem. 1998, 273, 669-672.
6. Taussig, R.; Gilman, A. G. Mammalian membrane-bound adenylyl cyclases. J. Biol. Chem. 1995, 270, 1-4.
7. Ishikawa, Y.; Homcy, C. J. The adenylyl cyclases as integrators of transmembrane signal transduction. Circ. Res. 1997, 80, 297-304.
8. Susanni, E. E.; Vatner, D. E.; Homcy, C. J. Beta-adrenergic receptor/adenylyl cyclase system. In The Heart and Cardiovascular System, 2nd ed.; Fozzard, H. A., Ed.; Raven Press: Ltd., New York, 1992.
9. Braunwald, E.; Zipes, D. P.; Libby, P. Treatment of heart failure: Pharmacological methods. In Heart Disease, 6th ed.; W. B. Saunders Company: Philadelphia, 1997.
10. Levy, D. E.; Marlowe, C.; Kane-Maguire, K.; Bao, M.; Cherbavaz, D. B.; Tomlinson, J. E.; Sedlock, D. M.; Scarborough, R. M. Hydroxamate based inhibitors of adenylyl cyclase. Part 1: The effect of acyclic linkers on P-site binding. Bioorg. Med. Chem. Lett. 2002, 12, 3085-3088.
11. Levy, D. E.; Bao, M.; Tomlinson, J. E.; Scarborough, R. M. Hydroxamate based inhibitors of adenylyl cyclase. Part 2: The effect of cyclic linkers on P-site binding. Bioorg. Med. Chem. Lett. 2002, 12, 3089-3092.
12. Dessauer, C. W.; Tesmer, J. J. G.; Sprang, S. R.; Gilman, A. G. The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol. Sci. 1999, 20, 205-210.
13. Tesmer, J. J. G.; Sunahara, R. K.; Johnson, R. A.; Gosselin, G.; Gilman, A. G.; Sprang, S. R. Two-metal-ion catalysis in adenylyl cyclase. Science 1999, 285, 756-760.
14. Texier, F.; Carrie, F. 1,3-Dipolar cycloadditions to compounds with activated unsaturated bonds. X. Addition of azidobenzenes to α-cyanoacrylic acid esters, α-cyanocinnamonitrile, α-cyanocinnamamide, and benzylidene malonic acid esters. Production of pyrrolidines. Bull. Soc. Chim. Fr. 1972, 258-263.
15. Trost, B. M.; Dietsche, T. J. New synthetic reactions. Asymmetric induction in allylic alkylations. J. Am. Chem. Soc. 1973, 95, 8200-8201.
16. Wu, Y.; Xu, J.-C.; Liu, J.; Jin, Y.-X. Synthesis of N-Boc and N-Fmoc dipeptoids with nucleobase residues as peptoid nucleic acid monomers. Tetrahedron 2001, 57, 3373-3381.
17. Toyota, A.; Katagiri, N.; Kaneko, C. Mitsunobu reactions for the synthesis of carbocyclic analogues of nucleosides: examination of the regioselectivity. Synthetic Commun. 1993, 23, 1295-1305.
18. Levy, D. E.; Lapierre, F.; Liang, W.; Ye, W.; Lange, C. W.; Li, X.; Grobelny, D.; Casabonne, M.; Tyrrell, D.; Holme, K.; Nadzan, A.; Galardy, R. E. Matrix metalloproteinase inhibitors: A structure activity study. J. Med. Chem. 1998, 41, 199-223.
19. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1, 1-28.
20. Kelley, J. L.; McLean, E. W.; Linn, J. A.; Krochmal, M. P.; Ferris, R. M.; Howard, J. L. Benzodiazepine receptor binding activity of 8-substituted-9-(3-substituted-benzyl)-6-(dimethylamino)-9Hpurines. J. Med. Chem. 1990, 33, 196-202.
21. Bellamy, F. D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in nonacidic and nonaqueous medium. Tetrahedron Lett. 1984, 25, 839-842.
22. 1 receptor. J. Med. Chem. 1991, 34, 2877-2882.